Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.62 |
| ▸ | CMA1 | P23946 | 13/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9699162 | 0.90 | CMA1 (0.58) | PREPCMA1ACECTSLKLK5 | |
| SCHEMBL9699156 | 0.90 | CMA1 (0.58) | PREPCMA1ACECTSLKLK5 | |
| SCHEMBL3469545 | 0.90 | PREP (0.65) | PREPCMA1ACEELANECTSL | |
| SCHEMBL10416187 | 0.90 | PREP (0.65) | PREPCMA1ACEELANECTSL | |
| SCHEMBL28545846 | 0.89 | PREP (0.61) | PREPCMA1ACECTSLKLK5 | |
| SCHEMBL7265704 | 0.89 | PREP (0.61) | PREPCMA1ACECTSLKLK5 | |
| SCHEMBL10882017 | 0.89 | PREP (0.61) | PREPCMA1ACECTSLKLK5 | |
| SCHEMBL9699149 | 0.89 | PREP (0.61) | PREPCMA1ACECTSLKLK5 | |
| SCHEMBL11517511 | 0.87 | PREP (0.70) | PREPCMA1ACEELANEREN | |
| SCHEMBL9699161 | 0.86 | CMA1 (0.65) | PREPCMA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PREP 16/4885CMA1 674/4885ACE 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.